Search ARM

Archived Publications & Presentations



Presentations

July 28th 2020

The Art of Gene Therapy Summit

Virtual

May 11th 2020

Valuing Transformative Therapies

Virtual

February 27th 2020

Landscape and Evolution of the Cell & Gene Therapy Marketplace

New York City

February 26th 2020

CAR-TCR Europe 2020: ATMP Market Access

London

February 25th 2020

CMC for CAR-T Therapies

London

February 25th 2020

Cell and Gene Therapy Workshop

New York City

February 7th 2020

ATMPs in Europe: State of Play

Berlin, Germany

January 22nd 2020

Regenerative Medicine Sector Overview

Miami, FL

January 13th 2020

Cell & Gene State of the Industry 2020

San Francisco, CA

December 12th 2019

Getting Ready: EU ATMP Access Event

Brussels, Belgium

October 29th 2019

ICMRA October 2019 Meeting

Rome, Italy

October 15th 2019

Advanced Therapies Sector Overview

London, UK

October 10th 2019

Gene Therapies: Sector Overview

New York City

October 3rd 2019

ARM's Role in the Sector

Carlsbad, CA

October 2nd 2019

Welcome to the Meeting on the Mesa

Carlsbad, CA

September 12th 2019

Cell & Gene Therapy Bioprocessing & Commercialization 2019

Boston, MA

September 12th 2019

Cross-Sector Efforts to Advance Cell & Gene Therapy Manufacturing

Boston, MA

August 27th 2019

Principles for Ethical Application of Gene Editing in the Clinic

Geneva, Switzerland

July 15th 2019

Regenerative Medicine Sector Overview

Boston, MA

June 13th 2019

Rare Disease Summit 2019: Advancements in Gene Therapy

Boston, MA

April 24th 2019

Meeting on the Med Day 2

Barcelona, Spain

April 23rd 2019

Meeting on the Mediterranean Day 1

Barcelona, Spain

March 28th 2019

3rd Annual Gene Therapy for Rare Disorders

Boston, MA

March 21st 2019

ARM's Cell & Gene Investor Day

New York, New York

February 27th 2019

Blood Centers of America Cell Therapy Workshop

New York, New York

February 7th 2019

DIA Europe 2019 - How to Facilitate Access to ATMPs in Europe

Vienna, Austria

January 23rd 2019

Phacilitate: Leaders World

Miami, Florida

January 7th 2019

2019 State of the Industry Briefing

San Francisco, CA

November 15th 2018

Bipartisan Policy Center Roundtable on Gene Therapy for Neurodegenerative Disease

Washington, DC

October 26th 2018

American Thrombosis and Hemostasis Network Data Summit

Chicago, IL

October 18th 2018

BIA UK Bioscience Forum 2018

London, UK

September 5th 2018

State of the Industry Update - Cell & Gene Therapy: Bioprocessing & Commercialization

Boston, MA

September 4th 2018

Cell & Gene Connect: Evolving Landscape of Cell & Gene Therapies

Boston, MA

May 22nd 2018

Alliance for Regenerative Medicine Policy Lunch

Washington, DC

March 1st 2018

ARM Advanced Therapies Summit

Amsterdam

January 1st 2018

ARM 2018 Cell & Gene Therapy State of the Industry

JP Morgan Biotech Showcase, San Francisco

November 1st 2017

ARM European Investor Day

London

Publications

A Wave of New Technology: Gene-Edited Therapies Produce First Clinical Data

June 18th 2020


Creating A Roadmap For The Development And Manufacture Of Gene Therapies

May 5th 2020


Bringing Regenerative Medicines to Patients in Need

February 28th 2020


Cell & Gene Therapy Insights

State of the Industry: The Financial, Clinical, and Scientific Landscape for Cell and Gene Therapies

January 31st 2020


In Vivo

Manufacturing Cures: Infrastructure Challenges Facing Cell And Gene Therapy Developers

June 10th 2019


Update on Regenerative Medicine Advanced Therapies Designations

May 13th 2019


Webinars

June 3rd 2020

Value-Based Payments 101

Potentially curative cell and gene therapies are changing the face of medicine and providing hope to patients where there was once none. But how will they be paid for? This webinar discusses the implementation of value-based payment models for innovative therapies.


May 27th 2020

Cell and Gene Therapy Market Access in a COVID-19 World

The webinar includes discussion around how COVID-19 changes the way we think about healthcare decision making and places intense pressure on financial management at all levels of the health system.


May 21st 2020

Cell Therapy Treatments for COVID-19

This webinar highlights potential treatments for Acute Respiratory Distress syndrome (ARDS) in COVID-19 patients. Two therapeutic developers, Athersys and Pluristem Therapeutics, presented on their treatment approaches and plans for near term clinical trials.


May 8th 2020

What Biotechs Need to Know About Fundraising in the Midst of COVID-19

Despite the immense economic challenges brought on by COVID-19, investment interest is still strong for both public and private companies in the cell and gene therapy space. This webinar discussed the current funding landscape, what investors are looking for when evaluating new and follow-on opportunities, and how companies can best prepare to fundraise in the midst of the pandemic.


April 10th 2020

FDA Clinical Trial Guidance During COVID-19

This webinar features FDA representatives Tejashri Purohit-Sheth and Ilan Irony from the Office of Tissues and Advanced Therapies, CBER, as they discuss the effect of COVID-19 on cell and gene therapy clinical trials. Discussion topics include assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.


April 7th 2020

Understanding the Coronavirus Emergency Loan Program for Small Businesses

This webinar features speakers Mary Beth Bosco, Nicole Elliott, and Joel Roberson, Partners at Holland & Knight LLP, to discuss the emergency loan program for small businesses established by the Coronavirus Aid, Relief, and Economic Security (CARES) Act. This fiscal stimulus program went live April 3, 2020 and loans will only be available until funds are exhausted, so the government is advising borrowers to apply as soon as possible.


September 19th 2019

Manufacturing Challenges Facing Cell & Gene Therapy Developers

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. Gain a deeper understanding of the many manufacturing and industrialization hurdles unique to bringing durable and even curative therapies to patients in need.


March 6th 2019

Introducing ARM: Regenerative Medicine in Europe

This webinar is intended to provide members of the press in Europe with an overview of the ATMP landscape in Europe, including major financings, the clinical pipeline, and the potential for these therapies to significantly improve the standard of care for many patients suffering from devastating diseases and disorders. The webinar also provides a brief introduction to ARM and ARM’s role in improving the landscape for ATMPs in Europe and globally.


June 13th 2018

RMAT Designation – Impact on Regenerative Medicine Sector

Gain a deeper understanding of the implications of the Regenerative Medicine Advanced Therapies (RMAT) designation and the significance of its support and advancement by the FDA in this webinar recording. Held in partnership with the Alliance for Regenerative Medicine (ARM), ARM, Informa Pharma Intelligence, and representative from Abeona, Athersys, and Enzyvant discuss the RMAT designation and its implications on the sector.


May 9th 2018

NTAP and the Next Generation of Cures

Michael Werner, Co-Founder and Senior Policy Counsel for ARM, and Robert Falb, Director of U.S. Policy and Advocacy, participated in BIO’s webinar on NTAP and advanced therapies on May 9. ARM believes that it is critical that the NTAP program be modernized to facilitate patient access to new and life-saving treatments.


October 24th 2017

CAR-T Approval: What’s Next?

CAR-T cell therapy is now approved in the U.S. The first product, Novartis’ Kymriah, is approved to treat pediatric and young adult patients with B-cell acute lymphoblastic lymphoma, and products for other oncological indications are hot on its heels. Join Informa Pharma Intelligence and ARM for an interactive webinar to explore what this historic approval means for the patient community, as well as how this sector will approach the scientific, clinical, policy and business issues surrounding CAR-T approvals.


Submitted Comments, Letters, Statements